Celularity Inc - FORM 8-K - EX-16.1 - LETTER FROM MARCUM LLP - July 22, 2021

Attached files

file filename
8-K - CURRENT REPORT - Celularity Incea144415-8k_celularityinc.htm
EX-4.1 - SPECIMEN COMMON STOCK CERTIFICATE OF THE COMPANY - Celularity Incea144415ex4-1_celularity.htm
EX-3.2 - AMENDED AND RESTATED BYLAWS OF CELULARITY INC. - Celularity Incea144415ex3-2_celularity.htm
EX-99.2 - UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION AS OF AND FOR THE Y - Celularity Incea144415ex99-2_celularity.htm
EX-99.1 - PRESS RELEASE DATED JULY 16, 2021 - Celularity Incea144415ex99-1_celularity.htm
EX-10.3 - AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT - Celularity Incea144415ex10-3_celularity.htm
EX-4.2 - SPECIMEN WARRANT CERTIFICATE OF THE COMPANY - Celularity Incea144415ex4-2_celularity.htm
EX-21.1 - LIST OF SUBSIDIARIES - Celularity Incea144415ex21-1_celularity.htm
EX-10.4 - VESTING AGREEMENT DATED AS OF JULY 16, 2021 BY AND AMONG GX SPONSOR LLC, CELULAR - Celularity Incea144415ex10-4_celularity.htm
EX-10.15 - FORM OF DEFERRED COMPENSATION GRANT NOTICE - Celularity Incea144415ex10-15_celularity.htm
EX-3.1 - AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CELULARITY INC. - Celularity Incea144415ex3-1_celularity.htm

Exhibit 16.1

 

 

 

July 21, 2021

 

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

Commissioners:

 

We have read the statements made by Celularity Inc. (formerly GX Acquisition Corp.) under Item 4.01 of its Form 8-K dated July 22, 2021. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Celularity Inc. (formerly GX Acquisition Corp.) contained therein.

 

Very truly yours,

 

/s/ Marcum llp

 

 

Marcum llp

 

 

 

 

Celularity Inc Reports